000			01863 a2200457 4500
005			20250516154856.0
264		0	_c20130827
008			201308s 0 0 eng d
022			_a1756-1833
024	7		_a10.1136/bmj.f3981 _2doi
040			_aNLM _beng _cNLM
100	1		_aRodgers, Mark A
245	0	0	_aReporting of industry funded study outcome data: comparison of confidential and published data on the safety and effectiveness of rhBMP-2 for spinal fusion. _h[electronic resource]
260			_bBMJ (Clinical research ed.) _cJun 2013
300			_af3981 p. _bdigital
500			_aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdverse Drug Reaction Reporting Systems _xorganization & administration
650	0	4	_aBone Morphogenetic Protein 2 _xadministration & dosage
650	0	4	_aDrug Industry _xeconomics
650	0	4	_aHumans
650	0	4	_aMeta-Analysis as Topic
650	0	4	_aOutcome and Process Assessment, Health Care _xmethods
650	0	4	_aPain Measurement _xstatistics & numerical data
650	0	4	_aPain, Postoperative _xdiagnosis
650	0	4	_aRandomized Controlled Trials as Topic
650	0	4	_aRecombinant Proteins _xadministration & dosage
650	0	4	_aResearch Design _xstandards
650	0	4	_aResearch Support as Topic
650	0	4	_aSpinal Fusion _xadverse effects
650	0	4	_aSystems Analysis
650	0	4	_aTransforming Growth Factor beta _xadministration & dosage
650	0	4	_aTreatment Outcome
700	1		_aBrown, Jennifer V E
700	1		_aHeirs, Morag K
700	1		_aHiggins, Julian P T
700	1		_aMannion, Richard J
700	1		_aSimmonds, Mark C
700	1		_aStewart, Lesley A
773	0		_tBMJ (Clinical research ed.) _gvol. 346 _gp. f3981
856	4	0	_uhttps://doi.org/10.1136/bmj.f3981 _zAvailable from publisher's website
999			_c22854434 _d22854434